Adagene Inc.

Healthcare · Biotechnology · China

Last price 2.51 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 168.53M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 ...